Chronic inflammatory diseases cause substantial individual suffering and cost to society. Most diseases lack cures, and available long-term medication relieves symptoms only at the expense of severe side effects. Insight into signals in leukocyte traffic pave the way for novel strategies to treat of chronic inflammation. Chemokine receptors relay their signal through phosphoinositide 3-kinase (PI3K) . We have recently demonstrated that the G protein-coupled PI3Kg acts as an essential regulator of leukocyte migration and adhesion, both key features of cell activation during the inflammatory process. This project is to validate PI3Kg and PI3Kd - both highly expressed in cells of haematopoietic origin - as drug targets. PI3K null mice shall be tested in chronic inflammation models. Studies of PI3K signalling in white blood cells shall elucidate the role of PI3Ks in chronic inflammation. Finally, selective PI3K inhibitors shall be produced.
Funding SchemeCSC - Cost-sharing contracts
W1W 7BS London
10126 Torino (Turin)